Lallemand Acquires BIO-CAT: US Enzyme & Microbial Capacity Significantly Boosted
Lallemand's acquisition of BIO-CAT, effective 31 July 2026, expands its US production footprint by two sites, enhancing enzyme and microbial manufacturing capabilities for the supplement sector.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Montréal-based Lallemand Inc. has finalised its acquisition of Virginia-based BIO-CAT Enzymes & Microbials, a move effective 31 July 2026 that significantly bolsters Lallemand's US manufacturing capabilities. While terms remain undisclosed, this strategic purchase integrates BIO-CAT's established expertise in single-to multi-enzyme blends, probiotics, and microbial solutions with Lallemand's extensive fermentation and life sciences portfolio. This integration is poised to accelerate innovation across human health and animal nutrition markets, directly impacting the availability and diversity of supplement ingredients.
BIO-CAT, founded in 1988, was an early pioneer in US dietary enzymes, developing key formulations for digestive preparations. Its existing facilities in Virginia and Minnesota will now integrate into Lallemand's network of over 45 global production sites. Lallemand CEO Antoine Chagnon stated the acquisition reinforces their presence in the dietary food supplement and health ingredient markets, expanding production capacity in the US. This expansion is crucial for meeting evolving customer demands and mitigating supply chain vulnerabilities previously highlighted by geopolitical factors and increasing ingredient lead times.
The combined entity leverages complementary technologies, including microbial fermentation and enzyme development, to offer a broader range of solutions. This synergistic approach aims to enhance product development cycles and improve speed to market for novel ingredient applications. For supplement brand owners, this translates to potential access to a more comprehensive ingredient catalogue and streamlined sourcing opportunities from a single, larger supplier, particularly for complex digestive health formulations.
What this means for United States
US supplement manufacturers and brand owners will benefit from enhanced domestic supply chain resilience for enzymes and microbial ingredients. Lallemand's expanded US footprint with two additional sites means reduced reliance on international logistics, potentially lowering freight costs and decreasing delivery times by 10-15% for critical ingredients. Procurement teams should re-evaluate existing supply agreements to leverage potential volume discounts and improved service levels from the consolidated Lallemand entity. Increased domestic production capacity may also foster a more competitive pricing environment for niche enzyme and probiotic blends, influencing formulation costs for new product development cycles over the next 12-24 months. Brands should assess supplier diversification strategies to capitalise on this enlarged, more integrated market player.
Many leading brands in this category are manufactured in partnership with Supplement Factory.